Biosimilar Switching Dispute: How to Fight Non-Medical Switching to Biosimilars

Biosimilars — highly similar versions of existing biologic drugs — have entered the US market in large numbers, creating significant cost-saving opportunities for payers. Insurers and PBMs have responded by aggressively moving stable patients from brand biologics to biosimilar alternatives, sometimes mid-treatment and without clinical consultation. If you are a patient on a brand biologic who has been told you must switch to a biosimilar, or if your insurer removed your brand biologic from the formulary, this guide explains your rights and how to appeal.

What Is Non-Medical Switching?

Non-medical switching is when an insurance company requires a patient to change medications — from a brand biologic to a biosimilar, from one biosimilar to another, or between different formulations — not because of a clinical reason, but solely because of cost, formulary changes, or contract negotiations. The patient's treating physician has not determined that the switch is appropriate; the insurer has made the determination unilaterally.

Common non-medical switching scenarios:

• Brand Humira removed from formulary in favor of Hadlima or Hyrimoz
• Brand Remicade replaced by Inflectra or Avsola
• Brand Stelara replaced by Wezlana or Otulfi biosimilar
• Brand Enbrel replaced by Eticovo or Erelzi

The Science Behind Biosimilar Switching Concerns

Therapeutic equivalence vs. interchangeability. The FDA evaluates biosimilars as "biosimilar" (highly similar with no clinically meaningful differences) or, for a higher standard, "interchangeable" (expected to produce the same clinical result as the reference product in any patient, and the risk of alternating does not increase safety or diminished efficacy concerns). Interchangeable biosimilars can be substituted by pharmacists without prescriber notification in most states.

However, most biosimilars on the market — particularly for injectable biologics like adalimumab, infliximab, and etanercept — do not hold interchangeability designations. Substitution by pharmacists requires prescriber consent in states without automatic substitution laws.

Immunogenicity risk. Biologics are large, complex proteins. The immune system can develop anti-drug antibodies (ADAs) against them. The concern with non-medical switching is that switching between different formulations — even highly similar ones — may trigger new ADA formation or alter the existing immunological tolerance. This concern is most relevant for:

• Patients who have been on brand therapy for years and achieved stable clinical response
• Patients co-administered immunosuppressants specifically to manage ADA formation
• Patients with prior ADA-related loss of response to a biologic

The nocebo effect. Clinical research has documented that patients who are aware they are being switched to a biosimilar — and who have concerns or distrust about the switch — experience worse outcomes than patients who switch without awareness or who consent voluntarily. This is the "nocebo effect" — negative expectation producing negative outcomes. For patients with well-established concerns about switching, the nocebo effect is a legitimate clinical consideration that physicians can document.

State Non-Medical Switching Laws

More than 25 states have enacted laws specifically restricting non-medical switching. These laws vary in scope but typically require:

• Prior written notice to the prescribing physician before implementing a formulary change that would require switching a stable patient
• A process by which the prescriber can certify that the switch is clinically inappropriate
• Continuation of the current drug at current cost-sharing levels while the prescriber certification is being evaluated
• Patient notification rights

States with strong non-medical switching protections include Arizona, California, Colorado, Florida, Illinois, New York, Texas, Virginia, and others. If you are in a protected state and your insurer is requiring a mid-therapy switch, citing the state statute in your appeal letter adds significant legal weight.

How to File a Biosimilar Switching Dispute

Step 1: Have your prescribing physician write a non-medical switching objection letter. This letter should state:

• The patient is currently stable on the brand biologic
• The switch is not being recommended for clinical reasons
• In the physician's clinical judgment, switching carries risk of immunogenicity, loss of response, or adverse clinical outcome
• The physician objects to the switch under any applicable state law
• The prescriber requests continuation of the current brand product without change

Step 2: File a formulary exception request. Request that the brand biologic be covered at formulary cost-sharing levels despite being moved to a non-preferred tier or removed from the formulary.

Step 3: Document clinical stability. Attach recent office visit notes demonstrating disease activity under control on the current biologic. Disease activity scores, lab markers (CRP, fecal calprotectin, PASI, DAS-28 as applicable), and quality of life assessments all support the stability argument.

Step 4: File a formal internal appeal if the exception is denied. Reiterate the non-medical switching legal argument, the immunogenicity concern, and the nocebo effect argument. Request External Independent Review: Complete Guide" class="auto-link">external review if the internal appeal fails.

When Switching to a Biosimilar Is Actually Appropriate

Biosimilar switching is not always inappropriate. For new prescriptions, starting with a biosimilar is often a reasonable clinical choice and is supported by rheumatology, gastroenterology, and dermatology guidelines. The switching disputes that are most winnable on appeal are those involving:

• Patients already stable on long-term brand therapy
• Mid-treatment switches without prescriber involvement
• Switches following formulary changes during an annual open enrollment period (rather than the patient's clinical transition period)

Fight Back With ClaimBack

Biosimilar switching disputes sit at the intersection of FDA science, state insurance law, and individual patient clinical stability. ClaimBack helps you make the full legal and clinical argument your insurer needs to hear.

Start your biosimilar switching appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal: What's the Difference?